Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
42 hedge funds and large institutions have $188M invested in Evofem Biosciences, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
28% more capital invested
Capital invested by funds: $147M → $188M (+$40.9M)
0% more funds holding
Funds holding: 42 → 42 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
+$18.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.68M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$512K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$430K |
| 5 |
State Street
Boston,
Massachusetts
|
+$393K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$157K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$123K |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
-$84.9K |
| 4 |
Millennium Management
New York
|
-$79K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$53K |
EVFM Hedge Fund Activity: Q4 2019 in Review
42 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2019, worth a combined $188M — up 28% from $147M a quarter earlier.
Fund positioning in EVFM was balanced in Q4 2019: 7 funds opened new positions, 7 closed out, 16 added to existing stakes and 8 trimmed.
The largest buyer was Schroder Investment Management Group, opening a new position worth an estimated $18.9M. The largest seller was Northern Trust, cutting an estimated $157K.
- 42 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $188M of Evofem Biosciences, Inc. Common Stock stock for Q4 2019, up 28% quarter-over-quarter.
- 7 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2019 and 7 closed out, a net change of 0 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q4 2019 was Schroder Investment Management Group, an estimated $18.9M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q4 2019 was Northern Trust, an estimated $157K sold.
Based on aggregated 13F filings for Q4 2019.